12 SCIENTIFIC SESSIONS DAILY NEWS | Day 1 Saturday, Nov. 16, 2024 AHA selects six Distinguished Scientists for 2024 Robert O. Bonow, MD, MS, FAHA Northwestern University | Feinberg School of Medicine Chicago Robert O. Bonow is the Goldberg Distinguished Professor of Cardiology at the Northwestern University Feinberg School of Medicine. He was senior investigator and deputy chief of the cardiology branch of the National Heart, Lung, and Blood Institute at the National Institutes of Health from 1980 to 1992 and was chief of the division of cardiology at Northwestern University Feinberg School of Medicine from 1992 to 2011. His research focuses on the application of cardiovascular imaging to investigate the natural history and clinical outcomes of people with valvular heart disease, hypertrophic cardiomyopathy and ischemic left ventricular dysfunction. He has been author or co-author of over 650 papers in the medical literature and 120 book chapters. He is editor-in-chief of JAMA Cardiology and an editor of Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Bonow has served on the Board of Scientific Counselors and Board of Extramural Advisors of the NHLBI and the Subspecialty Board on Cardiovascular Disease of the American Board of Internal Medicine. He is a past president of the American Heart Association, a Master of the American College of Cardiology and a Master of the American College of Physicians. Among his honors are the NIH Director’s Award and the U.S. Public Health Service Commendation Medal and Outstanding Service Medal. He is a recipient of the Distinguished Leadership Award, Distinguished Achievement Award, Gold Heart Award and James B. Herrick Award of the AHA; the Distinguished Fellowship Award, Distinguished Service Award and Distinguished Scientist Award of the American College of Cardiology; and the John Phillips Memorial Award of the American College of Physicians. Pedro J. del Nido, MD, FAHA Boston Children’s Hospital Pedro J. del Nido has been at the forefront of myocardial preservation and more recently has focused on creating reconstructive techniques for complex congenital heart defects. Recognizing a large unmet need, del Nido has worked to develop cardiac medical devices The American Heart Association is honoring six professional members with its Distinguished Scientist award for extraordinary contributions to cardiovascular and stroke research. Following are the 2024 awardees. The 2024 awardees will be honored during the Opening Session on Saturday, Nov. 16. Exploring the Next Chapter in the Groundbreaking CRISPR Journey: Getting to the Heart of the Matter This event is not part of the official Scientific Sessions 2024 as planned by the American Heart Association Committee on Scientific Sessions Programming. Intellia Therapeutics, and the Intellia Therapeutics logo are trademarks of Intellia Therapeutics, Inc., registered in the U.S. Patent and Trademark Office and other jurisdictions. © 2024. Intellia Therapeutics, Inc. Copying of this material by any means without Intellia’s prior written consent is prohibited. 129-NTLA-2001-2024.8.27-v2 Jim Januzzi, MD Hutter Family Professor of Medicine in the Field of Cardiology, Harvard Medical School Chief Scientific Officer, Baim Institute for Clinical Research Cardiologist, Corrigan Minehan Heart Center, Massachusetts General Hospital Boston, Massachusetts CHAIR AND SPEAKER: Mathew Maurer, MD Professor of Medicine, Arnold and Arlene Goldstein Professor of Cardiology, Director of the Cardiac Amyloidosis Program NewYork-Presbyterian and Columbia University Irving Medical Center New York, New York Jonathan Phillips, PhD Head of Pharmacology & Toxicology Intellia Therapeutics Cambridge, Massachusetts SPEAKERS: American Heart Association 2024 Saturday, November 16, 2024 12:30 PM – 1:15 PM CST Lunch to be provided Learning Studio I McCormick Place Convention Center Chicago, Illinois Join leading experts as they examine the progressive burden of transthyretin amyloidosis on patients. Explore how CRISPR/Cas9-mediated gene editing could potentially address unmet treatment needs in cardiology. The discussion will also cover considerations for the management of transthyretin amyloidosis, illustrated through in-depth analyses of two patient case studies. INTELLIA THERAPEUTICS LEARNING STUDIO PAID ADVERTISEMENT
RkJQdWJsaXNoZXIy MjI2NjI=